Rare Diseases Clinical Research Consortia (RDCRC) for Rare Diseases Clinical Research Network (U54)

The summary for the Rare Diseases Clinical Research Consortia (RDCRC) for Rare Diseases Clinical Research Network (U54) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Rare Diseases Clinical Research Consortia (RDCRC) for Rare Diseases Clinical Research Network (U54): The purpose of this FOA is to facilitate clinical research in rare diseases through support for 1) collaborative clinical research in rare diseases, including longitudinal studies of individuals with rare diseases, clinical studies and/or clinical trials; 2) training of clinical investigators in rare diseases research; 3) pilot/demonstration (proof of concepts) clinical research projects; and 4) access to information related to rare diseases for basic and clinical researchers, academic and practicing physicians, patients, and the lay public. Items 1-4 must be addressed in the RDCRC application. Clinical data management for efficient data collection as well as data mining and data sharing across rare diseases will be addressed in the DMCC application. Another FOA will be published to address DMCC.

Federal Grant Title:	Rare Diseases Clinical Research Consortia (RDCRC) for Rare Diseases Clinical Research Network (U54)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Food and Nutrition Health Income Security and Social Services
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-TR-13-002
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.121, 93.837, 93.838, 93.839, 93.846, 93.847, 93.853, 93.855, 93.856, 93.865
CFDA Descriptions:	Oral Diseases and Disorders Research; Cardiovascular Diseases Research; Lung Diseases Research; Blood Diseases and Resources Research; Arthritis, Musculoskeletal and Skin Diseases Research; Diabetes, Digestive, and Kidney Diseases Extramural Research; Extramural Research Programs in the Neurosciences and Neurological Disorders; Allergy, Immunology and Transplantation Research; Microbiology and Infectious Diseases Research; Child Health and Human Development Extramural Research
Current Application Deadline:	Nov 07, 2013
Original Application Deadline:	Nov 07, 2013
Posted Date:	Aug 13, 2013
Creation Date:	Aug 14, 2013
Archive Date:	Dec 08, 2013
Total Program Funding:	$17,500,000
Maximum Federal Grant Award:	$1,250,000
Minimum Federal Grant Award:	none
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
County governments
Others (see text field entitled "Additional Information on Eligibility" for clarification)
City or township governments
Native American tribal organizations (other than Federally recognized tribal governments)
Private institutions of higher education
Special district governments
Independent school districts
Native American tribal governments (Federally recognized)
For profit organizations other than small businesses
Public housing authorities/Indian housing authorities
State governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-13-002.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research ...; • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...; • NIDCR Mentoring Network to Promote a Diverse Dental, Oral and Craniofacial Research Workfo...; • Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparit...; • Epidemiological and Behavioral Research in Oral Health; • Metagenomic Analyses of the Oral Microbiome; • Phase Iii Clinical Trials in Oral Infectious Diseases
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...